Compare CRSP & BC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | BC |
|---|---|---|
| Founded | 2013 | 1845 |
| Country | Switzerland | United States |
| Employees | N/A | 14000 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.4B |
| IPO Year | 2016 | N/A |
| Metric | CRSP | BC |
|---|---|---|
| Price | $54.47 | $81.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 11 |
| Target Price | $70.29 | ★ $83.55 |
| AVG Volume (30 Days) | ★ 1.7M | 576.2K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.22% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,590,000.00 | N/A |
| Revenue This Year | $807.72 | $9.81 |
| Revenue Next Year | $172.52 | $5.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $44.12 | $54.73 |
| 52 Week High | $78.48 | $90.25 |
| Indicator | CRSP | BC |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 51.17 |
| Support Level | $47.48 | $78.23 |
| Resistance Level | $59.61 | $84.76 |
| Average True Range (ATR) | 2.84 | 2.87 |
| MACD | 0.25 | -0.08 |
| Stochastic Oscillator | 54.76 | 43.44 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns more than 450 Freedom Boat Club locations as well as Boateka, which facilitates transactions in the used-boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.